SOD1 and amyotrophic lateral sclerosis: Although most studies have only considered SOD1 levels as primary outcomes in CSF, SOD1 has been demonstrated to also be reduced in leukocytes in response to pyrimethamine treatment in genetic ALS with SOD1 mutation [77,83,84].